anti-interleukin-6 - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.08 [0.77, 1.52]< 10%6 studies (6/-)32.3 %highnot evaluable lowcrucial-
clinical improvement 1.17 [1.00, 1.38]> 10%5 studies (5/-)97.6 %highserious lowimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-
clinical worsening 0.78 [0.53, 1.14]< 136%4 studies (4/-)90.2 %some concernnot evaluable moderateimportant-
death or ventilation 0.59 [0.43, 0.80]< 10%5 studies (5/-)100.0 %highnot evaluable lowimportant-
hospital discharge 1.16 [0.90, 1.49]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-
ventilation 0.27 [0.14, 0.55]< 10%2 studies (2/-)100.0 %highnot evaluable lowimportant-
off oxygenation 1.46 [0.79, 2.68]> 128%2 studies (2/-)88.7 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 91, 90